Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
jtXaQ2sQg184mn4k
